why choose us

First received: February 21, 2023

Clinical Trial: AT278, NovoRapid® and Humulin® R (U500) in Glucose Clamp Study

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Diabetes Mellitus, Type 2

Study Type: INTERVENTIONAL


Official Title: A Phase 1, Single Centre, Single Dose, Randomised, Double-blind, Two-way Crossover, Glucose Clamp Study Investigating the Pharmacodynamics, Pharmacokinetics, and Safety of Ultra-rapid-acting Concentra

Brief Summary: This is a phase 1, single dose, randomised, double-blind, two-way crossover study to compare ultra-rapid-acting concentrated insulin aspart AT278 (U500/mL) with standard insulin aspart NovoRapid® (U100/mL) in participants with T2D.Participants and Investigators will be blinded to both study interventions.Humulin® R U-500 (U500/mL), a highly concentrated regular human insulin, will be used as an open-label comparator.

Read more